Literature DB >> 12761124

Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine.

Shannon L Harris1, Adam Finn, Dan M Granoff.   

Abstract

Polysaccharide-protein conjugate vaccines elicit higher concentrations of serum anticapsular antibody in infants and children than do unconjugated polysaccharide vaccines. The conjugate-induced antibodies also have higher avidity and complement-mediated bactericidal activity. Similar vaccine-related differences in the magnitude or functional activity of antibody are observed infrequently in immunized adults. We compared the antibody responses of adults immunized with an investigational group A and C meningococcal conjugate vaccine to those elicited by an unconjugated meningococcal polysaccharide vaccine. Although there were no significant differences between the respective geometric mean bactericidal titers of the two vaccine groups, it took, on average, three- to fourfold higher concentrations of polysaccharide-induced serum anticapsular antibody to achieve 50% complement-mediated bacteriolysis than conjugate-induced antibody (P < 0.001 for groups A and C). At limiting doses, the polysaccharide-induced anticapsular antibodies also were less effective in conferring passive protection against meningococcal bacteremia in infant rats challenged with a group C strain (P < 0.04). The avidity index of the group C antibodies was higher in the conjugate vaccine group than in the polysaccharide vaccine group (P < 0.005). The disparities in the functional activity of the anticapsular antibodies elicited in adults by the two vaccines imply fundamental differences in the respective B-cell populations stimulated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12761124      PMCID: PMC155780          DOI: 10.1128/IAI.71.6.3402-3408.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  49 in total

1.  Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England.

Authors:  M E Ramsay; N Andrews; E B Kaczmarski; E Miller
Journal:  Lancet       Date:  2001-01-20       Impact factor: 79.321

2.  IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines.

Authors:  A Soininen; I Seppälä; T Nieminen; J Eskola; H Käyhty
Journal:  Vaccine       Date:  1999-04-09       Impact factor: 3.641

3.  Importance of complement source in measuring meningococcal bactericidal titers.

Authors:  G F Santos; R R Deck; J Donnelly; W Blackwelder; D M Granoff
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

4.  Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naïve controls.

Authors:  R Borrow; J Southern; N Andrews; N Peake; R Rahim; M Acuna; S Martin; E Miller; E Kaczmarski
Journal:  Vaccine       Date:  2001-04-30       Impact factor: 3.641

Review 5.  Imperfect memory and the development of Haemophilus influenzae type B disease.

Authors:  A H Lucas; D M Granoff
Journal:  Pediatr Infect Dis J       Date:  2001-03       Impact factor: 2.129

Review 6.  Polysaccharide vaccines as probes of antibody repertoires in man.

Authors:  A H Lucas; D C Reason
Journal:  Immunol Rev       Date:  1999-10       Impact factor: 12.988

7.  Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults.

Authors:  T Wuorimaa; H Käyhty; O Leroy; J Eskola
Journal:  Vaccine       Date:  2001-02-28       Impact factor: 3.641

8.  Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine.

Authors:  P Richmond; E Kaczmarski; R Borrow; J Findlow; S Clark; R McCann; J Hill; M Barker; E Miller
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

9.  Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine.

Authors:  R Borrow; A J Fox; P C Richmond; S Clark; F Sadler; J Findlow; R Morris; N T Begg; K A Cartwright
Journal:  Epidemiol Infect       Date:  2000-06       Impact factor: 2.451

10.  Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.

Authors:  R Borrow; N Andrews; D Goldblatt; E Miller
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

View more
  8 in total

1.  Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Authors:  Lisa A Lewis; David M Vu; Dan M Granoff; Sanjay Ram
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

Review 2.  Review of meningococcal vaccines with updates on immunization in adults.

Authors:  Yorgo C Zahlanie; Moza M Hammadi; Soha T Ghanem; Ghassan S Dbaibo
Journal:  Hum Vaccin Immunother       Date:  2014-02-05       Impact factor: 3.452

3.  Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis.

Authors:  David M Vu; Jutamas Shaughnessy; Lisa A Lewis; Sanjay Ram; Peter A Rice; Dan M Granoff
Journal:  Infect Immun       Date:  2011-11-21       Impact factor: 3.441

4.  Neisseria lactamica antigens complexed with a novel cationic adjuvant.

Authors:  Emanuelle B Gaspar; Andreza S Rosetti; Nilton Lincopan; Elizabeth De Gaspari
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

Review 5.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

6.  Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine.

Authors:  Dan M Granoff; Amy Morgan; Jo Anne Welsch
Journal:  Pediatr Infect Dis J       Date:  2005-02       Impact factor: 2.129

Review 7.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

8.  Persistence of antibodies in laboratory staff immunized with quadrivalent meningococcal polysaccharide vaccine.

Authors:  Johannes Elias; Jamie Findlow; Ray Borrow; Angelika Tremmel; Matthias Frosch; Ulrich Vogel
Journal:  J Occup Med Toxicol       Date:  2013-03-04       Impact factor: 2.646

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.